Clinical Scenario for Choosing a Menin Inhibitor for Relapsed NPM1-Mutated AML

The moderator presents Clinical Scenario 1, the panelists then proceed to discuss how various factors that have been brought up in earlier episodes within this program impact their decisions for the patient in this clinical scenario. Some of these discussions are centered around drug-drug interactions, patient-specific comorbidities, and alternative factors. The panelists also delve into what to expect: the visit and monitoring schedule, when differentiation syndrome can occur, and obtaining labs. They close on how planning for transplant impacts the plan for the patient in this clinical scenario, including the short window to line up a donor and the need for disease control first.